Investors & News

Corporate Profile

Tengion’s first clinical program is the Neo-Kidney Augment™, which is intended to prevent or delay dialysis and transplantation by increasing renal function in patients with advanced chronic kidney disease (CKD). According to the United States Renal Data System, there are approximately 26 million adults in the U.S. who have chronic kidney disease (CKD), and there are 100,000 new patients who start on dialysis each year. $39 billion in direct U.S. costs each year are attributable to patients with end-stage renal disease, which is associated with an approximate 20% mortality rate per year and an average life expectancy of a patient initiating dialysis of approximately four years. The Neo-Ki... More >>

Recent News More >>
Upcoming Events More >>
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Investor Resources
TNGN(Common Stock)
ExchangeOTC BB (US Dollar)
Change (%)0.00 (0.00%)
Data as of 07/30/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
What's New
May 15, 2014
Tengion Reports First Quarter 2014 Financial Results
WINSTON-SALEM, N.C., May 15, 2014 (GLOBE NEWSWIRE) -- Tengion, Inc. (OTCQB:TNGN), a leader in regenerative medicine, today reported its financial results for the first quarter ended March 31, 2014. "We are actively continuing patient enrollment in our ongoing Phase 1 clinical trials for the Neo-Kidney Augment in both Sweden and in the United States. We are also working with key opinion leaders to determine future development plans for the Neo-Urinary Conduit," commented John L. Miclot, Presi... 
March 26, 2014
Tengion Reports Fourth Quarter and Full Year 2013 Financial Results
WINSTON-SALEM, N.C., March 26, 2014 (GLOBE NEWSWIRE) -- Tengion, Inc. (OTCQB:TNGN), a leader in regenerative medicine, today reported its financial results for the fourth quarter and full year ended December 31, 2013 and provided a business update. "We made important progress on our two lead clinical programs over the last year. We now have two Phase 1 clinical trials ongoing for the Neo-Kidney Augment, one in Sweden and the other recently initiated in the U.S. to implant up to 12 patients. ...